Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aurora Cannabis Inc (ACB) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance

Aurora Cannabis IncTrade
Charles River Laboratories Intl. IncTrade

Price performance (Past 24H)

Key statistics

Aurora Cannabis Inc vs Charles River Laboratories Intl. Inc — how do they compare? Aurora Cannabis Inc trades at $3.8 (market cap $223.59M), while Charles River Laboratories Intl. Inc trades at $287.58 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 60.2× Aurora Cannabis Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Aurora Cannabis Inc nearer its low. Which is the better fit depends on your goals.

ACBCRL
Market Cap
$223.59M$13.46B
Sector
HealthHealth
52-Week High
$6.23$282.00
52-Week Low
$2.58$145.57
Enterprise Value
$168.09M$16.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aurora Cannabis Inc

Aurora Cannabis (ACB) trades at $3.79, up 31.14% amid a hostile takeover bid from Curaleaf at $4 per share. The stock shows neutral technical signals with bearish moving averages. Fundamentally, 2025 revenue grew to $343.29M with a slim net profit of $1.59M, but 2026 projections indicate a net loss of $120M. Analyst consensus is mixed with 21.43% buy ratings, reflecting uncertainty over the acquisition offer and standalone prospects.

The outlook hinges on the takeover outcome; acceptance could provide immediate upside, while rejection may pressure shares given weak 2026 forecasts. Key risks include execution challenges, regulatory hurdles, and competitive pressures. Investors face a binary event driving near-term volatility.

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.

While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aurora Cannabis Inc

Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.

Read more on ACB

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL